GlobeNewsWire · REGN · November 12, 2026

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

Get the app for more

Explore stock news, insights and company research.